This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Quarter and half-year revenue decline, net loss
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 4.1 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone results for the quarter and six months ended 30 September 2026 show revenue of Rs 3.80 lakh for the quarter, unchanged year on year. Six-month revenue fell 32.7 percent to Rs 18.00 lakh from Rs 26.75 lakh. The quarter recorded a net loss of Rs 1.98 lakh against Rs 33,049 profit a year earlier. The six-month loss was Rs 51,569 against Rs 2.80 lakh profit. Operating cash flow was positive at Rs 1.93 lakh, with no borrowings reported.
Lower sales and losses may pressure the share price. Positive operating cash flow and no borrowings provide limited support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.09 Cr | −100.0% |
| Operating profit | −₹0.02 Cr | ₹0.00 Cr | −700.0% |
| Profit after tax | −₹0.02 Cr | ₹0.00 Cr | −700.0% |
| EBITDA margin | — | 4.6% | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.